Literature DB >> 28790112

Burden and Profile of Somatic Mutation in Duodenal Adenomas from Patients with Familial Adenomatous- and MUTYH-associated Polyposis.

Laura E Thomas1, Joanna J Hurley1,2, Elena Meuser1, Sian Jose1, Kevin E Ashelford1, Matthew Mort1, Shelley Idziaszczyk1, Julie Maynard1, Helena Leon Brito1, Manon Harry1, Angharad Walters1, Meera Raja1, Sarah-Jane Walton3, Sunil Dolwani1,4, Geraint T Williams1, Meleri Morgan5, Morgan Moorghen3,6, Susan K Clark3,7, Julian R Sampson8.   

Abstract

Purpose: Duodenal polyposis and cancer are important causes of morbidity and mortality in familial adenomatous polyposis (FAP) and MUTYH-associated polyposis (MAP). This study aimed to comprehensively characterize somatic genetic changes in FAP and MAP duodenal adenomas to better understand duodenal tumorigenesis in these disorders.Experimental Design: Sixty-nine adenomas were biopsied during endoscopy in 16 FAP and 10 MAP patients with duodenal polyposis. Ten FAP and 10 MAP adenomas and matched blood DNA samples were exome sequenced, 42 further adenomas underwent targeted sequencing, and 47 were studied by array comparative genomic hybridization. Findings in FAP and MAP duodenal adenomas were compared with each other and to the reported mutational landscape in FAP and MAP colorectal adenomas.
Results: MAP duodenal adenomas had significantly more protein-changing somatic mutations (P = 0.018), truncating mutations (P = 0.006), and copy number variants (P = 0.005) than FAP duodenal adenomas, even though MAP patients had lower Spigelman stage duodenal polyposis. Fifteen genes were significantly recurrently mutated. Targeted sequencing of APC, KRAS, PTCHD2, and PLCL1 identified further mutations in each of these genes in additional duodenal adenomas. In contrast to MAP and FAP colorectal adenomas, neither exome nor targeted sequencing identified WTX mutations (P = 0.0017).Conclusions: The mutational landscapes in FAP and MAP duodenal adenomas overlapped with, but had significant differences to those reported in colorectal adenomas. The significantly higher burden of somatic mutations in MAP than FAP duodenal adenomas despite lower Spigelman stage disease could increase cancer risk in the context of apparently less severe benign disease. Clin Cancer Res; 23(21); 6721-32. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28790112     DOI: 10.1158/1078-0432.CCR-17-1269

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

Review 1.  When you're strange: Unusual features of the MUTYH glycosylase and implications in cancer.

Authors:  Alan G Raetz; Sheila S David
Journal:  DNA Repair (Amst)       Date:  2019-06-08

Review 2.  MUTYH-associated tumor syndrome: The other face of MAP.

Authors:  Luigi Magrin; Daniele Fanale; Chiara Brando; Lidia Rita Corsini; Ugo Randazzo; Marianna Di Piazza; Vittorio Gurrera; Erika Pedone; Tancredi Didier Bazan Russo; Salvatore Vieni; Gianni Pantuso; Antonio Russo; Viviana Bazan
Journal:  Oncogene       Date:  2022-04-14       Impact factor: 9.867

3.  Inherited MUTYH mutations cause elevated somatic mutation rates and distinctive mutational signatures in normal human cells.

Authors:  Philip S Robinson; Laura E Thomas; Federico Abascal; Hyunchul Jung; Luke M R Harvey; Hannah D West; Sigurgeir Olafsson; Bernard C H Lee; Tim H H Coorens; Henry Lee-Six; Laura Butlin; Nicola Lander; Rebekah Truscott; Mathijs A Sanders; Stefanie V Lensing; Simon J A Buczacki; Rogier Ten Hoopen; Nicholas Coleman; Roxanne Brunton-Sim; Simon Rushbrook; Kourosh Saeb-Parsy; Fiona Lalloo; Peter J Campbell; Iñigo Martincorena; Julian R Sampson; Michael R Stratton
Journal:  Nat Commun       Date:  2022-07-08       Impact factor: 17.694

4.  Prognostic Nutritional Index Predicts Outcome of PD-L1 Negative and MSS Advanced Cancer Treated with PD-1 Inhibitors.

Authors:  Yan Zhang; Jun Jin; Min Tang; Ping Li; Li-Na Zhou; Yi-Ping Du; Min-Bin Chen
Journal:  Biomed Res Int       Date:  2022-06-06       Impact factor: 3.246

5.  Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG).

Authors:  Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill
Journal:  Gut       Date:  2019-11-28       Impact factor: 23.059

Review 6.  Discovering the Mutational Profile of Early Colorectal Lesions: A Translational Impact.

Authors:  Chiara Alquati; Anna Prossomariti; Giulia Piazzi; Francesco Buttitta; Franco Bazzoli; Luigi Laghi; Luigi Ricciardiello
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 7.  Small Bowel Epithelial Precursor Lesions: A Focus on Molecular Alterations.

Authors:  Alessandro Vanoli; Federica Grillo; Daniela Furlan; Giovanni Arpa; Oneda Grami; Camilla Guerini; Roberta Riboni; Luca Mastracci; Antonio Di Sabatino
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

8.  A Support Vector Machine Model Predicting the Risk of Duodenal Cancer in Patients with Familial Adenomatous Polyposis at the Transcript Levels.

Authors:  Weiqing Liu; Jian Dong; Shumin Ma; Lei Liang; Jun Yang
Journal:  Biomed Res Int       Date:  2020-06-16       Impact factor: 3.411

Review 9.  Endoscopic management of duodenal adenomatosis in familial adenomatous polyposis-A case-based review.

Authors:  E Soons; T M Bisseling; M C A van Kouwen; G Möslein; P D Siersema
Journal:  United European Gastroenterol J       Date:  2021-05-07       Impact factor: 4.623

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.